Facility ownership and mortality among older adults residing in care homes.

Autor: Javier Damián, Roberto Pastor-Barriuso, Fernando José García-López, Ana Ruigómez, Pablo Martínez-Martín, Jesús de Pedro-Cuesta

Publikováno v: PLoS ONE, Vol 14, Iss 3, p e0197789 (2019)

BACKGROUND AND OBJECTIVES:Nursing or care home characteristics may have a long-term impact on the residents' mortality risks that has not been studied previously. The study's main objective was to assess the association between facility ownership and

Externí odkaz: https://doaj.org/article/651d1840e4484638927934fab2a0adad

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism (deep vein thrombosis and pulmonary embolism) in four European countries

Autor: Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M. C. Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez

Background The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical prac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc0803de5229a790f8e984c72eae187e
https://doi.org/10.21203/rs.3.rs-2664836/v1

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network

Autor: Ana Ruigómez, Gunnar Brobert, Luis A. García Rodríguez, Pareen Vora

Publikováno v: Pharmacoepidemiology and Drug Safety

Purpose To describe the effect that validation of venous thromboembolism (VTE) coded entries in the health improvement network (THIN) has on incidence rates of VTE among a cohort of rivaroxaban/warfarin users. Methods Among 36 701 individuals with a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8705e153cd5801d1fb5fd739a60cfca
https://doi.org/10.1002/pds.5146

Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice

Autor: Miranda Davies, Luis A. García-Rodríguez, Gunnar Brobert, Tania Schink, Alison Evans, Pareen Vora, Ana Ruigómez, Saad A. W. Shakir, Kiliana Suzart-Woischnik, Leif Friberg, Mari-Ann Wallander, Yanina Balabanova, Ron M. C. Herings, Montse Soriano-Gabarró, Irene D. Bezemer

Publikováno v: Expert opinion on drug safety, 19(11), 1513-1520. Taylor and Francis Ltd.
Expert opinion on drug safety, 19(11):1513-1520
Garcia-Rodriguez, L A, Wallander, M A, Friberg, L, Ruigomez, A, Schink, T, Bezemer, I, Herings, R, Shakir, S, Evans, A, Davies, M, Suzart-Woischnik, K, Vora, P, Balabanova, Y, Soriano-Gabarro, M & Brobert, G 2020, ' Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice ', Expert opinion on drug safety, vol. 19, no. 11, pp. 1513-1520 . https://doi.org/10.1080/14740338.2020.1798928

BACKGROUND: Rivaroxaban is a highly selective factor Xa inhibitor approved for use in Europe for multiple indications. STUDY DESIGN AND METHODS: The European rivaroxaban epidemiological post-authorization safety study (PASS) program consists of seven

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f22a5e9fe6348bc402a6fbff69d4d5
https://research.vumc.nl/en/publications/2678d4a2-4f81-4c20-956c-4cc23def523a

Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe

Autor: Luis Alberto García Rodríguez, Montse Soriano-Gabarró, Pareen Vora, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Ana Ruigomez, Leif Friberg, Ron Herings, Karin M A Swart, Tania Schink, Elisabeth Smits, Annemarie Voss, Christine Tarenz, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya

Publikováno v: BMJ Open, Vol 14, Iss 3 (2024)

Objectives To describe opportunities and challenges experienced from the four pharmacoepidemiological database studies included in the rivaroxaban post authorisation safety study (PASS) programme and propose ways to maximise the value of population-b

Externí odkaz: https://doaj.org/article/71cd625a0f2244c3a4bb82474e3418be